Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer
(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/3/155 |
id |
doaj-8cd483acee5b4ce69a42dc68d7456823 |
---|---|
record_format |
Article |
spelling |
doaj-8cd483acee5b4ce69a42dc68d74568232021-09-20T10:09:58ZengMDPI AGCurrent Oncology1198-00521718-77292021-04-01281551663167210.3390/curroncol28030155Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical CancerSatomi Hattori0Nobuhisa Yoshikawa1Kazumasa Mogi2Kosuke Yoshida3Masato Yoshihara4Satoshi Tamauchi5Yoshiki Ikeda6Akira Yokoi7Kimihiro Nishino8Kaoru Niimi9Shiro Suzuki10Hiroaki Kajiyama11Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, JapanDepartment of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya 464-0021, JapanDepartment of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (<i>p</i> = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer.https://www.mdpi.com/1718-7729/28/3/155metastatic cervical cancertumor sizeconcurrent chemoradiotherapybiomarkerprognosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Satomi Hattori Nobuhisa Yoshikawa Kazumasa Mogi Kosuke Yoshida Masato Yoshihara Satoshi Tamauchi Yoshiki Ikeda Akira Yokoi Kimihiro Nishino Kaoru Niimi Shiro Suzuki Hiroaki Kajiyama |
spellingShingle |
Satomi Hattori Nobuhisa Yoshikawa Kazumasa Mogi Kosuke Yoshida Masato Yoshihara Satoshi Tamauchi Yoshiki Ikeda Akira Yokoi Kimihiro Nishino Kaoru Niimi Shiro Suzuki Hiroaki Kajiyama Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer Current Oncology metastatic cervical cancer tumor size concurrent chemoradiotherapy biomarker prognosis |
author_facet |
Satomi Hattori Nobuhisa Yoshikawa Kazumasa Mogi Kosuke Yoshida Masato Yoshihara Satoshi Tamauchi Yoshiki Ikeda Akira Yokoi Kimihiro Nishino Kaoru Niimi Shiro Suzuki Hiroaki Kajiyama |
author_sort |
Satomi Hattori |
title |
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer |
title_short |
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer |
title_full |
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer |
title_fullStr |
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer |
title_full_unstemmed |
Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer |
title_sort |
significance of concurrent chemoradiotherapy as primary treatment in patients with metastatic cervical cancer |
publisher |
MDPI AG |
series |
Current Oncology |
issn |
1198-0052 1718-7729 |
publishDate |
2021-04-01 |
description |
(1) This study investigated the prognostic impact of tumor size in patients with metastatic cervical cancer. (2) Methods: Seventy-three cervical cancer patients in our institute were stratified into two groups based on distant metastasis: para-aortic lymph node metastasis alone (IIIC2) or spread to distant visceral organs with or without para-aortic lymph node metastasis (IVB) to identify primary tumor size and concurrent chemoradiotherapy. (3) Results: The overall survival (OS) for patients with a tumor >6.9 cm in size was significantly poorer than that for patients with a tumor ≤6.9 cm in the IVB group (<i>p</i> = 0.0028); the corresponding five-year OS rates in patients with a tumor ≤6.9 and >6.9 cm were 53.3% and 13.4%, respectively. In the multivariate analysis, tumor size and primary treatment were significantly associated with survival in metastatic cervical cancer. (4) Conclusions: Tumor size ≤6.9 cm and concurrent chemoradiotherapy as the primary treatment were favorable prognostic factors for patients with metastatic cervical cancer. |
topic |
metastatic cervical cancer tumor size concurrent chemoradiotherapy biomarker prognosis |
url |
https://www.mdpi.com/1718-7729/28/3/155 |
work_keys_str_mv |
AT satomihattori significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT nobuhisayoshikawa significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT kazumasamogi significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT kosukeyoshida significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT masatoyoshihara significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT satoshitamauchi significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT yoshikiikeda significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT akirayokoi significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT kimihironishino significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT kaoruniimi significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT shirosuzuki significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer AT hiroakikajiyama significanceofconcurrentchemoradiotherapyasprimarytreatmentinpatientswithmetastaticcervicalcancer |
_version_ |
1717374606759690240 |